What's hot at SITC19 this year? We highlight half a dozen key presentations of interest to BSB readers and explain why they matter.
What new things will we learn about the microbiome at SITC19?
How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...
There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.
As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.
Where are CDK4/6 inhibitors going and are there new opportunities for this class of agents outside of HR+/HER2- breast cancer?
What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...
Highlights from the PROfound trial in advanced prostate cancer and other stories of interest
Key findings and commentary on the third day of ESMO
A look at the FLAURA overall survival results and what we can learn from the phase 3 trial
We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.
Review and analysis of key trials presented on the second day at ESMO 2019
Commentary and Insights from Day 1 of ESMO19
Some early stage oncology agents in development that seek to target and tackle inhibitory and immunosuppressive factors
Preview of ESMO19 around targeting DNA damage repair (DDR) for GU cancers.
What should we be watching out for in terms of red and green flags at ESMO on the breast cancer IO front?
Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space